Cadrenal Therapeutics, Inc. [CVKD]

Source: 

Company Overview

Cadrenal Therapeutics, Inc is developing tecarfarin, our drug candidate, forunmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designedto prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.